Related resources
Full-text held externally
- PMID: 23430159
- UKPMCID: 23430159
- DOI: 10.1007/s00213-013-2973-4
Search for item elsewhere
University researcher(s)
Academic department(s)
Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.
Schmechtig, Anne; Lees, Jane; Grayson, Lois; Craig, Kevin J; Dadhiwala, Rukiya; Dawson, Gerard R; Deakin, J F William; Dourish, Colin T; Koychev, Ivan; McMullen, Katrina; Migo, Ellen M; Perry, Charlotte; Wilkinson, Lawrence; Morris, Robin; Williams, Steve C R; Ettinger, Ulrich
Psychopharmacology. 2013;227(2):331-45.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 23430159
- UKPMCID: 23430159
- DOI: 10.1007/s00213-013-2973-4
Abstract
RATIONALE: The increasing demand to develop more efficient compounds to treat cognitive impairments in schizophrenia has led to the development of experimental model systems. One such model system combines the study of surrogate populations expressing high levels of schizotypy with oculomotor biomarkers. OBJECTIVES: We aimed (1) to replicate oculomotor deficits in a psychometric schizotypy sample and (2) to investigate whether the expected deficits can be remedied by compounds shown to ameliorate impairments in schizophrenia. METHODS: In this randomized double-blind, placebo-controlled study 233 healthy participants performed prosaccade (PS), antisaccade (AS) and smooth pursuit eye movement (SPEM) tasks after being randomly assigned to one of four drug groups (nicotine, risperidone, amisulpride, placebo). Participants were classified into medium- and high-schizotypy groups based on their scores on the Schizotypal Personality Questionnaire (SPQ, Raine (Schizophr Bull 17:555-564, 1991)). RESULTS: AS error rate showed a main effect of Drug (p < 0.01), with nicotine improving performance, and a Drug by Schizotypy interaction (p = 0.04), indicating higher error rates in medium schizotypes (p = 0.01) but not high schizotypes under risperidone compared to placebo. High schizotypes had higher error rates than medium schizotypes under placebo (p = 0.03). There was a main effect of Drug for saccadic peak velocity and SPEM velocity gain (both p ≤ 0.01) indicating impaired performance with risperidone. CONCLUSIONS: We replicate the observation of AS impairments in high schizotypy under placebo and show that nicotine enhances performance irrespective of group status. Caution should be exerted in applying this model as no beneficial effects of antipsychotics were seen in high schizotypes.